← Back to Search

Other

BNC210 for Post-Traumatic Stress Disorder (ATTUNE Trial)

Phase 2
Waitlist Available
Research Sponsored by Bionomics Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Summary

This trial will test whether the drug BNC210 is better than placebo at reducing symptoms of post-traumatic stress disorder (PTSD).

Eligible Conditions
  • Post Traumatic Stress Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Clinician Administered PTSD Scale for DSM-5 (CAPS-5)
Clinician Global Impression (CGI)
Hamilton Anxiety Rating Scale (HAM-A)
+5 more

Side effects data

From 2018 Phase 2 trial • 193 Patients • NCT02933606
8%
Upper Respiratory Tract Infection
8%
Diarrhoea
8%
Nausea
8%
Nasopharyngitis
6%
Headache
6%
Somnolence
6%
Dry Mouth
4%
Dizziness
4%
Fatigue
2%
Dyspepsia
2%
Viral Infection
100%
80%
60%
40%
20%
0%
Study treatment Arm
BNC210 600 mg b.i.d.
BNC210 300 mg b.i.d.
BNC210 150 mg b.i.d.
Placebo b.i.d.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: BNC210Experimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BNC210
2016
Completed Phase 2
~450

Find a Location

Who is running the clinical trial?

Bionomics LimitedLead Sponsor
6 Previous Clinical Trials
558 Total Patients Enrolled
~54 spots leftby Jul 2025